These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20031208)

  • 1. VPAC1 receptor binding site: contribution of photoaffinity labeling approach.
    Couvineau A; Ceraudo E; Tan YV; Laburthe M
    Neuropeptides; 2010 Apr; 44(2):127-32. PubMed ID: 20031208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
    Couvineau A; Tan YV; Ceraudo E; Lacapère JJ; Murail S; Neumann JM; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.
    Couvineau A; Tan YV; Ceraudo E; Laburthe M
    Methods Enzymol; 2013; 520():219-37. PubMed ID: 23332702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.
    Couvineau A; Laburthe M
    Br J Pharmacol; 2012 May; 166(1):42-50. PubMed ID: 21951273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
    Tan YV; Couvineau A; Lacapere JJ; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
    Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.
    Ceraudo E; Hierso R; Tan YV; Murail S; Rouyer-Fessard C; Nicole P; Robert JC; Jamin N; Neumann JM; Robberecht P; Laburthe M; Couvineau A
    FASEB J; 2012 May; 26(5):2060-71. PubMed ID: 22291440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
    Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.
    Ceraudo E; Murail S; Tan YV; Lacapère JJ; Neumann JM; Couvineau A; Laburthe M
    Mol Endocrinol; 2008 Jan; 22(1):147-55. PubMed ID: 17885205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The VPAC1 receptor: structure and function of a class B GPCR prototype.
    Couvineau A; Ceraudo E; Tan YV; Nicole P; Laburthe M
    Front Endocrinol (Lausanne); 2012; 3():139. PubMed ID: 23162538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.
    Ceraudo E; Tan YV; Nicole P; Couvineau A; Laburthe M
    J Mol Neurosci; 2008 Nov; 36(1-3):245-8. PubMed ID: 18597186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.
    Laburthe M; Couvineau A; Tan V
    Peptides; 2007 Sep; 28(9):1631-9. PubMed ID: 17574305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
    Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
    Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.
    Tan YV; Couvineau A; Murail S; Ceraudo E; Neumann JM; Lacapère JJ; Laburthe M
    J Biol Chem; 2006 May; 281(18):12792-8. PubMed ID: 16520374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor.
    Couvineau A; Robert JC; Ramdani T; Lacapère JJ; Rouyer-Fessard C; Laburthe M
    J Mol Neurosci; 2008 Nov; 36(1-3):249-53. PubMed ID: 18592417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D; Ribeiro JA; Sebastião AM
    Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.